PAS — Pascal Biosciences Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Nov | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pascal Biosciences Inc. is a Canada-based biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer. The Company is engaged in the research and development of products for the treatment of cancers and for improvement of the immune system. The Company operates in the segment of biotechnology research and development. Its cannabinoid portfolio includes PAS-403, PAS-393 and Cannabinoid for corona virus disease-2019 (COVID-19). Its PAS-403 is a small molecule therapeutics for the treatment of glioblastoma. Its PAS-393 is an immune-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy for cancer treatment. The pre-BCR antibody targets leukemia cells without harming the normal immune system.
Directors
- Patrick Gray CHM (58)
- Robert Gietl PRE (56)
- Mark Van Der Horst PRE
- Hardy Forzley CFO
- Thomas Deckwerth VPR
- Larry Tjoelker VPR
- Kevin Egan VBD
- Jens Biertumpel DRC
- Thomas Gadek IND
- Terry Pearson IND (73)
- H. Michael Shepard IND (66)
- Last Annual
- November 30th, 2022
- Last Interim
- February 28th, 2023
- Incorporated
- January 28th, 2011
- Public Since
- March 16th, 2012
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 65,594,769
- Address
- 880 - 580 Hornby Street, Null, VANCOUVER, V6C 3B6
- Web
- https://www.pascalbiosciences.com/
- Phone
- +1 6048060626
- Auditors
- Smythe LLP
Upcoming Events for PAS
Similar to PAS
Arch Biopartners
TSX Venture Exchange
biOasis Technologies
TSX Venture Exchange
Ceapro
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
FAQ
As of Today at 01:17 UTC, shares in Pascal Biosciences are trading at CA$0.02. This share price information is delayed by 15 minutes.
Shares in Pascal Biosciences last closed at CA$0.02 and the price had moved by -78.95% over the past 365 days. In terms of relative price strength the Pascal Biosciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -78.47% over the past year.
There is no consensus recommendation for this security.
Find out morePascal Biosciences does not currently pay a dividend.
Pascal Biosciences does not currently pay a dividend.
Pascal Biosciences does not currently pay a dividend.
To buy shares in Pascal Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.02, shares in Pascal Biosciences had a market capitalisation of .
Here are the trading details for Pascal Biosciences:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: PAS
Based on an overall assessment of its quality, value and momentum Pascal Biosciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pascal Biosciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -54.9%.
As of the last closing price of CA$0.02, shares in Pascal Biosciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pascal Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pascal Biosciences' management team is headed by:
- Patrick Gray - CHM
- Robert Gietl - PRE
- Mark Van Der Horst - PRE
- Hardy Forzley - CFO
- Thomas Deckwerth - VPR
- Larry Tjoelker - VPR
- Kevin Egan - VBD
- Jens Biertumpel - DRC
- Thomas Gadek - IND
- Terry Pearson - IND
- H. Michael Shepard - IND